Mesoblast Stock Performance
| MESO Stock | USD 17.99 2.04 12.79% |
On a scale of 0 to 100, Mesoblast holds a performance score of 6. The company secures a Beta (Market Risk) of 0.22, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Mesoblast's returns are expected to increase less than the market. However, during the bear market, the loss of holding Mesoblast is expected to be smaller as well. Please check Mesoblast's potential upside, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether Mesoblast's current price movements will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Mesoblast are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, Mesoblast displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 5.2 | Five Day Return (3.29) | Year To Date Return (7.60) | Ten Year Return 71.22 | All Time Return 441.29 |
Last Split Factor 1:2 | Last Split Date 2024-01-10 |
1 | Independent Study Presented at American Society of Hematology Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment f... | 12/11/2025 |
2 | Mesoblast Sales Surge 60 percent in December Quarter, Bolstered by New Financing | 01/08/2026 |
3 | Mesoblast Stock Rises On Strong YearOverYear Growth In Ryoncil Sales | 01/09/2026 |
4 | Mesoblast Stock Price Down 5.5 percent - Heres What Happened - MarketBeat | 01/13/2026 |
5 | Mesoblast Is Down 6.4 percent After Encouraging FDA Feedback On Back Pain Cell Therapy Data Has The Bull Case Changed | 01/22/2026 |
6 | Mesoblast Valuation Check As Ryoncil Access And Early Commercial Outcomes Progress | 01/28/2026 |
7 | Mesoblast Is Down 7.4 percent After Expanding Ryoncil Access And Planning Adult SR-aGvHD Trial Has The Bull Case Changed | 02/05/2026 |
| Begin Period Cash Flow | 63 M | |
| Total Cashflows From Investing Activities | 120 K |
Mesoblast | Build AI portfolio with Mesoblast Stock |
Mesoblast Relative Risk vs. Return Landscape
If you would invest 1,570 in Mesoblast on November 12, 2025 and sell it today you would earn a total of 229.00 from holding Mesoblast or generate 14.59% return on investment over 90 days. Mesoblast is currently generating 0.2916% in daily expected returns and assumes 3.7433% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Mesoblast, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mesoblast Target Price Odds to finish over Current Price
The tendency of Mesoblast Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 17.99 | 90 days | 17.99 | about 35.35 |
Based on a normal probability distribution, the odds of Mesoblast to move above the current price in 90 days from now is about 35.35 (This Mesoblast probability density function shows the probability of Mesoblast Stock to fall within a particular range of prices over 90 days) .
Mesoblast Price Density |
| Price |
Predictive Modules for Mesoblast
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Mesoblast. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mesoblast's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Mesoblast Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Mesoblast is not an exception. The market had few large corrections towards the Mesoblast's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Mesoblast, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Mesoblast within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.01 | |
β | Beta against Dow Jones | 0.22 | |
σ | Overall volatility | 1.57 | |
Ir | Information ratio | -0.02 |
Mesoblast Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Mesoblast for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Mesoblast can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Mesoblast had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 17.2 M. Net Loss for the year was (102.14 M) with loss before overhead, payroll, taxes, and interest of (22.74 M). | |
| Mesoblast currently holds about 85.5 M in cash with (49.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62. | |
| Latest headline from simplywall.st: Mesoblast Is Down 7.4 percent After Expanding Ryoncil Access And Planning Adult SR-aGvHD Trial Has The Bull Case Changed |
Mesoblast Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Mesoblast Stock often depends not only on the future outlook of the current and potential Mesoblast's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Mesoblast's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 120.8 M | |
| Cash And Short Term Investments | 161.2 M |
Mesoblast Fundamentals Growth
Mesoblast Stock prices reflect investors' perceptions of the future prospects and financial health of Mesoblast, and Mesoblast fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mesoblast Stock performance.
| Return On Equity | -0.19 | ||||
| Return On Asset | -0.0537 | ||||
| Operating Margin | (3.02) % | ||||
| Current Valuation | 1.96 B | ||||
| Shares Outstanding | 128.29 M | ||||
| Price To Earning | (5.90) X | ||||
| Price To Book | 3.45 X | ||||
| Price To Sales | 123.06 X | ||||
| Revenue | 17.2 M | ||||
| Gross Profit | (22.74 M) | ||||
| EBITDA | (73.66 M) | ||||
| Net Income | (102.14 M) | ||||
| Cash And Equivalents | 85.5 M | ||||
| Cash Per Share | 0.62 X | ||||
| Total Debt | 128.16 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 1.90 X | ||||
| Book Value Per Share | 0.47 X | ||||
| Cash Flow From Operations | (49.95 M) | ||||
| Earnings Per Share | (0.85) X | ||||
| Market Capitalization | 1.94 B | ||||
| Total Asset | 784.68 M | ||||
| Retained Earnings | (1.01 B) | ||||
| Working Capital | 101.72 M | ||||
| Current Asset | 88.82 M | ||||
| Current Liabilities | 29.41 M | ||||
About Mesoblast Performance
By examining Mesoblast's fundamental ratios, stakeholders can obtain critical insights into Mesoblast's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Mesoblast is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.8 K | 1.1 K | |
| Return On Tangible Assets | (0.55) | (0.58) | |
| Return On Capital Employed | (0.08) | (0.09) | |
| Return On Assets | (0.13) | (0.12) | |
| Return On Equity | (0.15) | (0.16) |
Things to note about Mesoblast performance evaluation
Checking the ongoing alerts about Mesoblast for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mesoblast help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mesoblast had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 17.2 M. Net Loss for the year was (102.14 M) with loss before overhead, payroll, taxes, and interest of (22.74 M). | |
| Mesoblast currently holds about 85.5 M in cash with (49.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62. | |
| Latest headline from simplywall.st: Mesoblast Is Down 7.4 percent After Expanding Ryoncil Access And Planning Adult SR-aGvHD Trial Has The Bull Case Changed |
- Analyzing Mesoblast's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mesoblast's stock is overvalued or undervalued compared to its peers.
- Examining Mesoblast's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mesoblast's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mesoblast's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mesoblast's stock. These opinions can provide insight into Mesoblast's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Will Biotechnology sector continue expanding? Could Mesoblast diversify its offerings? Factors like these will boost the valuation of Mesoblast. Expected growth trajectory for Mesoblast significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mesoblast data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.85) | Revenue Per Share | Quarterly Revenue Growth 4.586 | Return On Assets | Return On Equity |
Investors evaluate Mesoblast using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mesoblast's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mesoblast's market price to deviate significantly from intrinsic value.
Understanding that Mesoblast's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mesoblast represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mesoblast's market price signifies the transaction level at which participants voluntarily complete trades.